J&J's Janssen Seeks FDA OK of Tremfya in Active Psoriatic Arthritis

Date : 09/16/2019 @ 12:16PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 141.38  0.04 (0.03%) @ 1:00AM
After Hours
Last Trade
Last $ 141.38 ◊ 0.00 (0.00%)

J&J's Janssen Seeks FDA OK of Tremfya in Active Psoriatic Arthritis

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Monday said it filed a supplemental biologics-license application with the U.S. Food and Drug Administration seeking first-in-class approval of Tremfya for adults with active psoriatic arthritis.

Janssen said it also expects to submit a marketing application to the European Medicines Agency for the same indication before the end of the year.

The company said it is estimated that at least one million Americans suffer from psoriatic arthritis, chronic disease characterized by joint inflammation, enthesitis, dactylitis and the skin manifestations of psoriasis.

The FDA approved Tremfya in July 2017 for adults with moderate to severe plaque psoriasis.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

September 16, 2019 08:01 ET (12:01 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.